Affimed N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AFMD research report →
About the company
Affimed N. V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region.
- CEO
- Shawn Leland
- IPO
- 2014
- Employees
- 76
- HQ
- Mannheim, DE
Price Chart
- Market Cap
- $2.98M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1288.95%
- Net Margin
- -1280.22%
- ROE
- -100.55%
- ROIC
- -137.41%
- Revenue
- $8.28M · -79.99%
- Net Income
- $-105,938,000 · -23.18%
- EPS
- $-7.09 · -17.38%
- Op Income
- $-106,661,000
- FCF YoY
- -7.96%
- 52W High
- $8.95
- 52W Low
- $0.02
- 50D MA
- $0.50
- 200D MA
- $1.76
- Beta
- 2.07
- Avg Volume
- 15.65M
Get TickerSpark's AI analysis on AFMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AFMD coverage
Recent articles, reports, and earnings notes.
No research on AFMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AFMD report →Similar companies
Peers in the same neighborhood.